|
EDX Medical Group PLC - Cambridge, England-based firm that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Announces plans to launch a new ‘highly accurate’ testicular cancer early detection test, which will be available ‘within weeks’ in the UK. Says the TC100 assay, which analyses multiple specific tumour biomarkers and prepares a report for clinicians ‘using a proprietary AI-powered algorithm’, ‘features exceptional sensitivity...and also detects cancer recurrences at ultra-high accuracy with 100% sensitivity following treatment and during ongoing surveillance of testicular cancer survivors’. Says over 30 study reports have confirmed the assay’s clinical accuracy and potential clinical usefulness in primary diagnosis, early detection, metastatic disease and recurrence of both seminoma and non-seminoma testicular cancer. Chief Executive Officer Mike Hudson says: ‘The highly sensitive ’TC100’ testicular cancer test will help doctors to accurately identify testicular cancer early and better manage the safe and effective care of their patients. The quick confirmation of early signs of disease, the absence of cancer following treatment and to monitor any signs of recurrence during surveillance will help minimise scans, biopsies and the unnecessary use of toxic chemotherapy, significantly improving quality of life for patients.’ Current stock price: 13.00 pence, up 6.1% in London on Friday afternoon 12-month change: up 30% Copyright 2025 Alliance News Ltd. All Rights Reserved
|
